Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Simulations PlusSLP -0.14%82 Cash-to-Debt is 102.65 as of May. 2026, which is 1% below its 10-year median of 103.62. GuruFocus rates SLP with a GF Score™ of 82/100 and a GF Value™ of $35.19 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 673 Healthcare Providers & Services companies, Simulations Plus ranks better than 91.23% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Simulations Plus's cash to debt ratio for the quarter that ended in May. 2026 was 102.65.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Simulations Pluscould pay off its debt using the cash in hand for the quarter that ended in May. 2026.
The historical rank and industry rank for Simulations Plus's Cash-to-Debt or its related term are showing as below:
SLP'
s Cash-to-Debt Range Over the Past 10 Years
Min: 7.25 Med: 103.62 Max: No Debt
Current: 102.65
During the past 13 years, Simulations Plus's highest Cash to Debt Ratio was No Debt. The lowest was 7.25. And the median was 103.62.
SLP's Cash-to-Debt is ranked better than 91.23% of 673
companies
in the Healthcare Providers & Services industry
Industry Median: 0.79
vs SLP: 102.65
Simulations Plus (NAS:SLP) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Simulations Plus Cash-to-Debt Related Terms
Simulations Plus Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Simulations Plus's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Health Information Services subindustry, Simulations Plus's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simulations Plus Cash-to-Debt vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Simulations Plus's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Simulations Plus's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simulations Plus (SLP) has a Cash-to-Debt of 102.65 as of May. 2026. This is near median its historical median of 103.62. Over the past decade, Simulations Plus' Cash-to-Debt has ranged from 7.25 to 10,000.00. According to the industry distribution chart, Simulations Plus ranks #59 out of 673 companies in the Healthcare Providers & Services industry, placing it in the top 8.8%.
Is Simulations Plus' Cash-to-Debt too high?
Simulations Plus' current Cash-to-Debt of 102.65 is near median its 10-year median of 103.62. Over the past 10 years, this metric has ranged from a low of 7.25 to a high of 10,000.00. The Healthcare Providers & Services industry median Cash-to-Debt is 0.79. Simulations Plus' value of 102.65 is 12893.7% above this industry median. Based on the distribution chart, Simulations Plus ranks #59 out of 673 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Simulations Plus has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Simulations Plus' Cash-to-Debt compare to CTEV and TBRG?
According to the Healthcare Providers & Services industry distribution chart, Simulations Plus ranks #59 out of 673 companies for Cash-to-Debt. This places Simulations Plus in the top 9% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 0.79. Simulations Plus' value of 102.65 is 12893.7% above this benchmark. Historically, Simulations Plus' own Cash-to-Debt has ranged from 7.25 to 10,000.00 over the past decade. While the company's 10-year median is 103.62 vs. the industry median of 0.79, Simulations Plus has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Healthcare Providers & Services company?
The median Cash-to-Debt among Healthcare Providers & Services companies is 0.79, based on 673 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Simulations Plus's current Cash-to-Debt of 102.65 is 12893.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Cash-to-Debt is 0.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simulations Plus's current Cash-to-Debt is 102.65, which is near median its own 10-year median of 103.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simulations Plus stock overvalued right now?
Based on GuruFocus' analysis, Simulations Plus (SLP) is currently considered Significantly Undervalued. The stock's GF Value™ is $35.19, compared to a current price of $18.40 — trading 47.7% below its estimated fair value. The current Cash-to-Debt is 102.65, which is near median its 10-year median of 103.62 and 12893.7% above the Healthcare Providers & Services industry median of 0.79. Simulations Plus' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Simulations Plus (SLP), the current Cash-to-Debt is 102.65 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simulations Plus (SLP) Overvalued in 2026?
Based on GuruFocus' analysis, Simulations Plus stock appears to be undervalued.
The current stock price of $18.40 is trading 47.7% below its estimated GF Value™ of $35.19.
GuruFocus considers Simulations Plus to be Significantly Undervalued.
Key valuation signals for SLP:
Cash-to-Debt: 102.65 (near median its 10-year median of 103.62)
GF Value™: $35.19 vs. price of $18.40 (47.7% below fair value)
Industry Position: 12893.7% above the Healthcare Providers & Services median (#59 of 673)
No single metric tells the full story. See the SLP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
82GF Score
Get the complete analysis for SLP
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLP has been successfully added to your 
